Breast Cancer Clinical Trials in Durham, North Carolina

17 studies are recruiting for breast cancer in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Identifying Patterns in the Breath of Individuals With Breast Cancer

   Researchers will compare the breath profiles of women with breast cancer and those without to determine whether there are disease-specific patterns that can be leveraged to facilitate breast cancer detection. Women with mammogram-confirmed breast tissue density undergoing standard-of-care breast ca…

   Stage

   Not phased

   Ages

   40 to 74

   Site

   Duke University Medical Cente, Durham, North Carolina

   Locations

   5 in total

   Run by

   Breathe BioMedical Inc

   See if you can join NCT06512350 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

   The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke Cancer Institute, Durham, North Carolina

   Locations

   567 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06492616 on ClinicalTrials.gov

4. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

   This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke Cancer Institute, Durham, North Carolina

   Locations

   241 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06790693 on ClinicalTrials.gov

5. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

6. ATEMPT 2.0: Adjuvant T-DM1 vs TH

   This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   53 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04893109 on ClinicalTrials.gov

7. Weight Management After Cancer for Survivors in Rural Communities

   This study is testing a new program called WeCan-Rural, designed to help breast cancer survivors manage symptoms and build healthy habits like eating well, staying active, and managing their weight. These changes may help lower the risk of heart disease after cancer treatment. The study will answer…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   5 in total

   Run by

   Duke University

   See if you can join NCT07426952 on ClinicalTrials.gov

8. Behavioral Pain Intervention for Older Cancer Patients

   This randomized controlled trial examines a 1-session, telehealth pain coping skills training (PCST) protocol with five 15-minute maintenance calls (Brief PCST-Community) adapted for women with breast cancer in medically underserved areas. Pain, health-related quality of life, and self-efficacy for…

   Stage

   Not phased

   Ages

   55 and older

   Site

   Duke Cancer Network, Durham, North Carolina

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT07300995 on ClinicalTrials.gov

9. Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

   This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke University/Duke Cancer Center, Durham, North Carolina

   Locations

   54 in total

   Run by

   University Hospital, Basel, Switzerland

   See if you can join NCT07140172 on ClinicalTrials.gov

10. DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

    The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Duke University Medical Center, Durham, North Carolina

    Locations

    3 in total

    Run by

    Nancy Lin, MD

    See if you can join NCT06176261 on ClinicalTrials.gov

11. Planning Grant for TOPS for Breast Cancer Survivors

    The purpose of this study is to help make a community led weight loss program known as Take Off Pounds Sensibly (TOPS) more relevant for breast cancer survivors. This study is made up to two parts. The first part includes using focus groups to review current materials that the investigators plan to…

    Stage

    Not phased

    Ages

    21 to 90

    Site

    Duke University, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT06658912 on ClinicalTrials.gov

12. A Study of a Decision Tool for People Considering Breast Reconstruction Surgery

    The purpose of this study is to find out whether it is practical (feasible) to do a larger study looking at the effectiveness of the Breast Reconstruction Decision Aid Tool (RECONJOINT) for breast reconstruction surgery.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke Cancer Institute (Data collection only), Durham, North Carolina

    Locations

    9 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07335354 on ClinicalTrials.gov

13. SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

    Investigators aim to conduct a type 1 hybrid effectiveness-implementation surgeon-level cluster randomized clinical trial (RCT) of a multi-level intervention, a shared decision making training for surgeons plus patient decision aid vs. usual care (UC), at 7 large health systems across the U.S. to l…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke University, Durham, North Carolina

    Locations

    11 in total

    Run by

    Beth Israel Deaconess Medical Center

    See if you can join NCT06896474 on ClinicalTrials.gov

14. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Duke Cancer Center/ DUMC, Durham, North Carolina

    Locations

    18 in total

    Run by

    Incyclix Bio

    See if you can join NCT05735080 on ClinicalTrials.gov

15. Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

    The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke, Durham, North Carolina

    Locations

    7 in total

    Run by

    Carevive Systems, Inc.

    See if you can join NCT05974150 on ClinicalTrials.gov

16. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Duke Cancer Institute, Durham, North Carolina

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

17. Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors

    The purpose of this study is to determine the effectiveness of a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and engage in recommended follow-up care.

    Stage

    Not phased

    Ages

    18 to 39

    Site

    Duke Cancer Institute, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT06371768 on ClinicalTrials.gov